IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.62%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$297M
AUM Growth
-$31.7M
Cap. Flow
-$5.36M
Cap. Flow %
-1.8%
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5
Avg Time Held
1.8 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$11M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.45M
3
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$8.21M
4
BIIB icon
Biogen
BIIB
+$7.81M
5
GILD icon
Gilead Sciences
GILD
+$6.85M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
2
APLS icon
Apellis Pharmaceuticals
APLS
+$11.8M
3
AMGN icon
Amgen
AMGN
+$9.48M
4
HRMY icon
Harmony Biosciences
HRMY
+$8.89M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
INSM icon
51
Insmed
INSM
$21.4B
$1.01M 0.34%
40,100
– –
2019 Q1
18 quarters
BPMC icon
52
DELISTED
Blueprint Medicines
BPMC
$1M 0.34%
+20,000
New +$1.07M
2023 Q3
0 quarters
AKRO icon
53
DELISTED
Akero Therapeutics
AKRO
$935K 0.32%
18,489
-60,000
-76% -$2.79M
2023 Q2
1 quarter
KZR icon
54
DELISTED
Kezar Life Sciences
KZR
$831K 0.28%
+70,383
New +$1.25M
2023 Q3
0 quarters
NTLA icon
55
Intellia Therapeutics
NTLA
$1.6B
$758K 0.26%
24,000
– –
2021 Q4
7 quarters
PRTA icon
56
Prothena Corp
PRTA
$430M
$723K 0.24%
+15,000
New +$891K
2023 Q3
0 quarters
AGIO icon
57
Agios Pharmaceuticals
AGIO
$1.85B
$594K 0.2%
24,000
– –
2023 Q2
1 quarter
BEAM icon
58
Beam Therapeutics
BEAM
$2.44B
$565K 0.19%
23,500
– –
2022 Q2
5 quarters
VTYX icon
59
DELISTED
Ventyx Biosciences
VTYX
$521K 0.18%
15,000
– –
2023 Q1
2 quarters
VIR icon
60
Vir Biotechnology
VIR
$1.76B
$440K 0.15%
+47,000
New +$670K
2023 Q3
0 quarters
NBP icon
61
NovaBridge Biosciences American Depositary Shares
NBP
$148M
$410K 0.14%
310,499
– –
2021 Q1
10 quarters
PTCT icon
62
PTC Therapeutics
PTCT
$4.98B
$381K 0.13%
17,000
– –
2019 Q1
18 quarters
ARVN icon
63
Arvinas
ARVN
$446M
$334K 0.11%
17,000
– –
2022 Q3
4 quarters
PTGX icon
64
Protagonist Therapeutics
PTGX
$8.82B
$332K 0.11%
19,900
– –
2023 Q2
1 quarter
RLMD icon
65
Relmada Therapeutics
RLMD
$346M
$30K 0.01%
10,000
– –
2021 Q3
8 quarters
APLS icon
66
DELISTED
Apellis Pharmaceuticals
APLS
– –
-129,700
Closed -$11.8M –
HCM icon
67
HUTCHMED
HCM
$2.34B
– –
-68,000
Closed -$816K –
SAGE icon
68
DELISTED
Sage Therapeutics
SAGE
– –
-20,000
Closed -$939K –
TVTX icon
69
Travere Therapeutics
TVTX
$5.02B
– –
-441,019
Closed -$6.77M –
HZNP
70
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-67,000
Closed -$6.89M –
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2023 Portfolio in Review

As of Q3 2023, International Biotechnology Trust held 70 positions worth $297M, down 9.6% from $329M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust's Q3 2023 filing shows 9 new, 18 increased, 13 reduced and 5 closed positions. Its largest new stake was CRISPR Therapeutics: 63,000 shares worth $2.86M. The largest sale was Regeneron Pharmaceuticals, an estimated $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2023 buy was CRISPR Therapeutics: 63,000 shares worth $2.86M.
  • International Biotechnology Trust added most to uniQure in Q3 2023, an estimated $11M increase.
  • International Biotechnology Trust's biggest Q3 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.3M.
  • International Biotechnology Trust fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $11.8M.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $297M portfolio in Q3 2023.
  • International Biotechnology Trust opened 9 new positions and closed 5 in Q3 2023.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $297M.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.